POC5

Summary

POC5 (POC5 centriolar protein, HGNC:26658) is a protein-coding gene on chromosome 5q13.3, encoding Centrosomal protein POC5 (Q8NA72). Essential for the assembly of the distal half of centrioles, required for centriole elongation.

Involved in centriole elongation and negative regulation of centriole elongation. Located in centriole and centrosome.

Source: NCBI Gene 134359 — RefSeq curated summary.

At a glance

• Gene–disease (curated): ciliopathy (Strong, GenCC) — +2 more curated relationships
• GWAS associations: 58
• Clinical variants (ClinVar): 401 total — 1 pathogenic
• Phenotypes (HPO): 2
• MANE Select transcript: NM_001099271

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26658
Approved symbol	POC5
Name	POC5 centriolar protein
Location	5q13.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ35779, MGC120442, MGC120443, MGC120444, hPOC5
Ensembl gene	ENSG00000152359
Ensembl biotype	protein_coding
OMIM	617880
Entrez	134359

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 12 protein_coding, 4 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000357564, ENST00000428202, ENST00000446329, ENST00000502826, ENST00000503521, ENST00000503835, ENST00000504862, ENST00000506164, ENST00000507421, ENST00000508467, ENST00000510798, ENST00000512125, ENST00000514838, ENST00000515285, ENST00000904656, ENST00000904657, ENST00000930834, ENST00000930835, ENST00000930836

RefSeq mRNA: 2 — MANE Select: NM_001099271 NM_001099271, NM_152408

CCDS: CCDS47236, CCDS47237

Canonical transcript exons

ENST00000428202 — 12 exons

Exon	Start	End
ENSE00001004832	75677774	75677950
ENSE00001004834	75690383	75690562
ENSE00001004835	75685207	75685484
ENSE00001004837	75689012	75689165
ENSE00001663438	75692396	75692500
ENSE00002026374	75674124	75674578
ENSE00002080052	75717306	75717437
ENSE00003487925	75694655	75694831
ENSE00003508537	75707737	75707875
ENSE00003521620	75702605	75702810
ENSE00003560151	75712854	75712951
ENSE00003586083	75705704	75705787

Expression profiles

Bgee: expression breadth ubiquitous, 224 present calls, max score 94.12.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.3272 / max 159.4089, expressed in 1762 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
62141	14.3047	1762
62140	0.0224	3

Top tissues by expression

246 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	94.12	gold quality
oocyte	CL:0000023	94.06	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.77	gold quality
calcaneal tendon	UBERON:0003701	87.78	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.42	gold quality
right uterine tube	UBERON:0001302	87.36	gold quality
adrenal tissue	UBERON:0018303	85.08	gold quality
right testis	UBERON:0004534	84.73	gold quality
sperm	CL:0000019	84.71	gold quality
left testis	UBERON:0004533	84.58	gold quality
testis	UBERON:0000473	84.10	gold quality
smooth muscle tissue	UBERON:0001135	83.77	gold quality
monocyte	CL:0000576	83.71	gold quality
leukocyte	CL:0000738	83.60	gold quality
granulocyte	CL:0000094	83.42	gold quality
ventricular zone	UBERON:0003053	83.30	gold quality
right ovary	UBERON:0002118	82.12	gold quality
spleen	UBERON:0002106	81.87	gold quality
islet of Langerhans	UBERON:0000006	81.85	gold quality
left ovary	UBERON:0002119	81.62	gold quality
vermiform appendix	UBERON:0001154	81.52	gold quality
ileal mucosa	UBERON:0000331	81.42	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	81.18	gold quality
body of uterus	UBERON:0009853	81.15	gold quality
lymph node	UBERON:0000029	81.13	gold quality
endocervix	UBERON:0000458	80.66	gold quality
tibialis anterior	UBERON:0001385	80.54	silver quality
body of pancreas	UBERON:0001150	80.33	gold quality
tendon	UBERON:0000043	80.31	gold quality
ganglionic eminence	UBERON:0004023	80.20	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-6386	no	476.75
E-ANND-3	no	3.82

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

23 targeting POC5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-8076	99.78	68.52	1170
HSA-MIR-543	99.52	69.03	2595
HSA-MIR-330-3P	99.41	69.95	2521
HSA-MIR-2054	99.20	68.89	1699
HSA-MIR-6877-3P	98.98	65.83	560
HSA-MIR-6819-3P	98.95	65.57	572
HSA-MIR-4451	98.82	68.17	1455
HSA-MIR-302F	98.44	69.02	1776
HSA-MIR-1245B-3P	98.01	68.91	1387
HSA-MIR-643	97.35	67.91	805
HSA-MIR-4286	97.20	64.37	1587
HSA-MIR-3667-5P	97.16	64.87	591
HSA-MIR-7109-3P	94.23	67.19	743
HSA-MIR-4732-5P	90.07	64.77	412

Literature-anchored findings (GeneRIF, showing 9)

• hPOC5, a conserved centrin-binding protein that contains Sfi1p-like repeats is characterized. (PMID:19349582)
• Data indicate that overexpression of the centrin interactor POC5 leads to the assembly of linear, centrin-dependent structures. (PMID:23844208)
• Mutations in the POC5 gene contribute to the occurrence of idiopathic scoliosis. (PMID:25642776)
• Depletion of CEP295 blocks the incorporation of POC5 and POC1B into the distal portion of centrioles and suppresses the post-translational modification of centriolar microtubules . Our study thus uncovers a new role for CEP295 during centriole elongation. (PMID:27185865)
• Common variant rs6892146 of POC5 is associated with the development of adolescent idiopathic scoliosis in the Chinese population. (PMID:29189569)
• The findings demonstrate that Poc5 is important for normal retinal development and function. Altogether, this study presents POC5 as a novel gene involved autosomal recessively inherited RP, and strengthens the hypothesis that mutations in centriolar proteins are important cause of retinal dystrophies. (PMID:29272404)
• POC5 mutation is associated with impairment of cell cycle, cilia length and centrosome protein interactions in Adolescent idiopathic scoliosis. (PMID:30845169)
• Prevalence of POC5 Coding Variants in French-Canadian and British AIS Cohort. (PMID:34356048)
• Differential Regulation of POC5 by ERalpha in Human Normal and Scoliotic Cells. (PMID:37239471)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Poc5	ENSMUSG00000021671
rattus_norvegicus	Poc5	ENSRNOG00000018193

Protein

Protein identifiers

Centrosomal protein POC5 — Q8NA72 (reviewed: Q8NA72)

Alternative names: Protein of centriole 5

All UniProt accessions (6): Q8NA72, D6RBC1, D6RDG4, D6REA5, D6RIH2, D6RJ06

UniProt curated annotations — full annotation on UniProt →

Function. Essential for the assembly of the distal half of centrioles, required for centriole elongation. Acts as a negative regulator of centriole elongation.

Subunit / interactions. Interacts with CETN2 and CETN3. Forms a microtubule-associated complex with POC1B, CETN2 and FAM161A. Interacts with CCDC15.

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Centriole.

Post-translational modifications. Hyperphosphorylated during recruitment to procentrioles in G2/M phase.

Similarity. Belongs to the POC5 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8NA72-1	1	yes
Q8NA72-2	2
Q8NA72-3	3

RefSeq proteins (2): NP_001092741, NP_689621 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR033351	POC5	Family

UniProt features (23 total): modified residue 4, repeat 3, splice variant 3, sequence variant 3, region of interest 3, compositionally biased region 2, sequence conflict 2, coiled-coil region 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NA72-F1	65.76	0.36

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 105, 109, 538, 564

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 132 (showing top): GOBP_NEUROGENESIS, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_ANIMAL_ORGAN_MORPHOGENESIS, GOBP_EYE_PHOTORECEPTOR_CELL_DIFFERENTIATION, GOBP_CENTRIOLE_ASSEMBLY, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_CELL_CYCLE, GOCC_CENTROSOME, GOBP_PHOTORECEPTOR_CELL_DEVELOPMENT, GOBP_ORGANELLE_ASSEMBLY, GOBP_PHOTORECEPTOR_CELL_DIFFERENTIATION, FISCHER_DREAM_TARGETS, GOCC_NEURON_PROJECTION, GOBP_SENSORY_ORGAN_DEVELOPMENT

GO Biological Process (3): eye photoreceptor cell development (GO:0042462), centriole elongation (GO:0061511), negative regulation of centriole elongation (GO:1903723)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): centrosome (GO:0005813), centriole (GO:0005814), photoreceptor connecting cilium (GO:0032391), cytoplasm (GO:0005737), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
microtubule organizing center	2
intracellular membraneless organelle	2
eye photoreceptor cell differentiation	1
photoreceptor cell development	1
centriole replication	1
cell cycle process	1
negative regulation of cell cycle process	1
centriole elongation	1
regulation of centriole elongation	1
binding	1
centriole	1
ciliary transition zone	1
photoreceptor cell cilium	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

961 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
POC5	POC1B	Q8TC44	961
POC5	FAM161A	Q3B820	913
POC5	WDR90	Q96KV7	871
POC5	CETN2	P41208	776
POC5	CEP135	Q66GS9	755
POC5	CPAP	Q9HC77	729
POC5	SASS6	Q6UVJ0	724
POC5	CEP120	Q8N960	720
POC5	CCP110	O43303	711
POC5	CETN1	Q12798	709
POC5	SPICE1	Q8N0Z3	705
POC5	SFI1	A8K8P3	694
POC5	CNTROB	Q8N137	657
POC5	CEP295	Q9C0D2	653
POC5	RTTN	Q86VV8	650

IntAct

56 interactions, top by confidence:

A	B	Type	Score
POC5	CETN3	psi-mi:“MI:0915”(physical association)	0.920
POC5	CETN2	psi-mi:“MI:0915”(physical association)	0.920
CETN2	POC5	psi-mi:“MI:0915”(physical association)	0.920
CETN3	POC5	psi-mi:“MI:0915”(physical association)	0.920
POC5	CETN3	psi-mi:“MI:0914”(association)	0.920
CETN1	POC5	psi-mi:“MI:0915”(physical association)	0.850
POC5	CETN1	psi-mi:“MI:0915”(physical association)	0.850
POC5	FAM161A	psi-mi:“MI:0915”(physical association)	0.800
FAM161A	POC5	psi-mi:“MI:0915”(physical association)	0.800
CETN2	SFI1	psi-mi:“MI:0914”(association)	0.740
CETN1	SFI1	psi-mi:“MI:0914”(association)	0.640

BioGRID (130): POC5 (Two-hybrid), POC5 (Two-hybrid), POC5 (Two-hybrid), POC5 (Two-hybrid), POC5 (Proximity Label-MS), POC5 (Proximity Label-MS), ABCE1 (Proximity Label-MS), AGK (Proximity Label-MS), AKIP1 (Proximity Label-MS), ALMS1 (Proximity Label-MS), ATAD3A (Proximity Label-MS), ATP5L (Proximity Label-MS), CEP131 (Proximity Label-MS), CCDC138 (Proximity Label-MS), CCDC14 (Proximity Label-MS)

ESM2 similar proteins: A0PJP4, A2AHJ4, A4IIZ9, D3YZP9, F4HRI2, F4HRV8, I6PL68, O09000, O75665, O94967, P49140, P51948, P70365, Q0IHE5, Q15788, Q16204, Q17QG3, Q2QLI6, Q3LGD4, Q3SYW5, Q4PJW2, Q4R3X1, Q4R8G4, Q4V891, Q5R8Q4, Q5RD40, Q5RKN3, Q5ZKF4, Q5ZLY0, Q62739, Q653N3, Q66IJ0, Q68FY1, Q86Z20, Q8CFE5, Q8CGF6, Q8L7S4, Q8NA72, Q8NFH5, Q8R4R6

Diamond homologs: Q4R8G4, Q4V891, Q6DFB7, Q8NA72, Q9DBS8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 30 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Loss of Nlp from mitotic centrosomes	5	39.6×	2e-05
Loss of proteins required for interphase microtubule organization from the centrosome	5	39.6×	2e-05
AURKA Activation by TPX2	5	38.1×	2e-05
Recruitment of mitotic centrosome proteins and complexes	5	34.0×	2e-05
Regulation of PLK1 Activity at G2/M Transition	5	31.7×	2e-05
Recruitment of NuMA to mitotic centrosomes	5	29.1×	3e-05
Anchoring of the basal body to the plasma membrane	5	28.3×	3e-05
Cell Cycle, Mitotic	5	12.1×	1e-03

GO biological processes:

GO term	Partners	Fold	FDR
microtubule cytoskeleton organization	5	23.3×	3e-04
cilium assembly	7	19.8×	1e-05
cell division	6	10.7×	8e-04
protein transport	5	8.4×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

401 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	245
Likely benign	110
Benign	22

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
3899921	NM_001099271.2(POC5):c.1211C>T (p.Ser404Leu)	Pathogenic

SpliceAI

2604 predictions. Top by Δscore:

Variant	Effect	Δscore
5:75674577:TG:T	acceptor_gain	1.0000
5:75677882:T:TA	donor_gain	1.0000
5:75677947:CATA:C	acceptor_gain	1.0000
5:75677949:TA:T	acceptor_gain	1.0000
5:75677951:C:CC	acceptor_gain	1.0000
5:75689007:CTAA:C	donor_loss	1.0000
5:75689008:TAA:T	donor_loss	1.0000
5:75689009:AAC:A	donor_loss	1.0000
5:75689010:ACC:A	donor_loss	1.0000
5:75689011:C:CG	donor_loss	1.0000
5:75689011:CCTG:C	donor_gain	1.0000
5:75689065:ACACC:A	donor_gain	1.0000
5:75689066:CACCC:C	donor_gain	1.0000
5:75689161:GATAA:G	acceptor_gain	1.0000
5:75689162:ATAA:A	acceptor_gain	1.0000
5:75689163:TAA:T	acceptor_gain	1.0000
5:75689164:AA:A	acceptor_gain	1.0000
5:75689164:AACTA:A	acceptor_loss	1.0000
5:75689165:ACTAA:A	acceptor_loss	1.0000
5:75689166:C:CC	acceptor_gain	1.0000
5:75689166:CTA:C	acceptor_loss	1.0000
5:75689167:T:G	acceptor_loss	1.0000
5:75689171:A:AC	acceptor_gain	1.0000
5:75690379:TTA:T	donor_loss	1.0000
5:75690380:TA:T	donor_loss	1.0000
5:75690381:A:AC	donor_gain	1.0000
5:75690381:AC:A	donor_gain	1.0000
5:75690382:C:CT	donor_gain	1.0000
5:75690382:CC:C	donor_gain	1.0000
5:75690382:CCA:C	donor_gain	1.0000

AlphaMissense

3759 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:75689050:A:G	L364P	0.999
5:75689052:A:C	N363K	0.999
5:75689052:A:T	N363K	0.999
5:75689056:A:G	L362S	0.999
5:75689069:C:G	G358R	0.999
5:75689073:C:A	M356I	0.999
5:75689073:C:G	M356I	0.999
5:75689073:C:T	M356I	0.999
5:75689074:A:G	M356T	0.999
5:75689077:A:G	F355S	0.999
5:75689045:C:G	A366P	0.998
5:75689054:T:C	N363D	0.998
5:75689063:A:G	C360R	0.998
5:75689068:C:T	G358D	0.998
5:75689070:C:A	R357S	0.998
5:75689070:C:G	R357S	0.998
5:75689076:G:C	F355L	0.998
5:75689076:G:T	F355L	0.998
5:75689078:A:G	F355L	0.998
5:75689061:A:C	C360W	0.997
5:75689062:C:T	C360Y	0.997
5:75689071:C:A	R357M	0.997
5:75689071:C:G	R357T	0.997
5:75689077:A:C	F355C	0.997
5:75689031:A:C	F370L	0.996
5:75689031:A:T	F370L	0.996
5:75689033:A:G	F370L	0.996
5:75689044:G:T	A366D	0.996
5:75689047:T:A	E365V	0.996
5:75689053:T:A	N363I	0.996

dbSNP variants (sampled 300 via entrez): RS1000074655 (5:75678955 G>A), RS1000135244 (5:75694332 A>G), RS1000164934 (5:75677012 C>T), RS1000166954 (5:75685994 A>G), RS1000196100 (5:75684753 T>C), RS1000262215 (5:75685715 G>T), RS1000286547 (5:75688167 T>C), RS1000366387 (5:75719391 A>C), RS1000496261 (5:75689198 T>A,G), RS1000554399 (5:75679274 C>A), RS1000774418 (5:75692904 C>A,G,T), RS1000899938 (5:75702420 C>T), RS1000918162 (5:75711850 C>T), RS1001028542 (5:75709696 G>A), RS1001057017 (5:75712193 G>A,C,T)

Disease associations

OMIM: gene MIM:617880 | disease phenotypes: MIM:181800, MIM:268000

GenCC curated gene-disease

Disease	Classification	Inheritance
ciliopathy	Strong	Autosomal recessive
scoliosis	Strong	Autosomal dominant
retinitis pigmentosa	Limited	Autosomal recessive

Mondo (6): optic atrophy (MONDO:0003608), inherited retinal dystrophy (MONDO:0019118), scoliosis, isolated, susceptibility to, 1 (MONDO:0008419), retinitis pigmentosa (MONDO:0019200), scoliosis (MONDO:0005392), ciliopathy (MONDO:0005308)

Orphanet (3): OBSOLETE: Inherited retinal disorder (Orphanet:71862), Retinitis pigmentosa (Orphanet:791), OBSOLETE: Syndromic rod-cone dystrophy (Orphanet:98661)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0000556	Retinal dystrophy
HP:0002650	Scoliosis

GWAS associations

58 associations (top):

Study	Trait	p-value
GCST000830_32	Body mass index	2.000000e-13
GCST001953_13	Obesity	3.000000e-12
GCST001953_33	Obesity	4.000000e-09
GCST001953_63	Obesity	1.000000e-08
GCST002461_19	Body mass index	4.000000e-06
GCST002783_265	Body mass index	2.000000e-17
GCST002783_38	Body mass index	3.000000e-13
GCST002783_620	Body mass index	6.000000e-17
GCST002783_66	Body mass index	5.000000e-07
GCST004065_67	Waist circumference	2.000000e-13
GCST004065_97	Waist circumference	3.000000e-13
GCST004066_3	Hip circumference	7.000000e-11
GCST004066_82	Hip circumference	1.000000e-11
GCST004280_6	Diastolic blood pressure	1.000000e-08
GCST004495_7	BMI (adjusted for smoking behaviour)	5.000000e-08
GCST004495_8	BMI (adjusted for smoking behaviour)	1.000000e-13
GCST004495_9	BMI (adjusted for smoking behaviour)	4.000000e-07
GCST004497_79	Body mass index (joint analysis main effects and smoking interaction)	2.000000e-12
GCST004497_80	Body mass index (joint analysis main effects and smoking interaction)	6.000000e-08
GCST004497_81	Body mass index (joint analysis main effects and smoking interaction)	7.000000e-07
GCST004499_11	BMI in non-smokers	2.000000e-06
GCST004499_12	BMI in non-smokers	6.000000e-12
GCST004499_13	BMI in non-smokers	3.000000e-08
GCST004557_166	Body mass index	3.000000e-09
GCST004557_185	Body mass index	6.000000e-06
GCST004557_215	Body mass index	4.000000e-06
GCST004557_50	Body mass index	6.000000e-10
GCST004558_198	Body mass index (joint analysis main effects and physical activity interaction)	2.000000e-06
GCST004558_234	Body mass index (joint analysis main effects and physical activity interaction)	5.000000e-09
GCST004558_86	Body mass index (joint analysis main effects and physical activity interaction)	1.000000e-08

EFO canonical traits (12, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0006336	diastolic blood pressure
EFO:0004318	smoking behavior
EFO:0008002	physical activity measurement
EFO:0004574	total cholesterol measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0005763	pulse pressure measurement
EFO:0004338	body weight
EFO:0008336	disease progression measurement
EFO:0009766	asparagine measurement
EFO:0000195	metabolic syndrome
EFO:0009819	comparative body size at age 10, self-reported

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D009896	Optic Atrophy	C10.292.700.225; C11.640.451
D058499	Retinal Dystrophies	C11.768.585.658
D012174	Retinitis Pigmentosa	C11.270.684; C11.768.585.658.500; C16.320.290.684
D012600	Scoliosis	C05.116.900.800.875

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, increases expression	2
Cyclosporine	increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	decreases expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
abrine	increases expression	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Acetaminophen	increases expression	1
Benzo(a)pyrene	affects methylation	1
Estradiol	increases expression	1
Methyl Methanesulfonate	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Silicon Dioxide	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Aflatoxin B1	decreases methylation	1
Cadmium Chloride	decreases expression	1
Thapsigargin	increases expression	1
Okadaic Acid	increases expression	1
Copper Sulfate	increases expression	1

Clinical trials (associated diseases)

473 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00508066	PHASE4	COMPLETED	Continuous Local Infusion of Anesthetic at the Incisional Site for Scoliosis Surgery
NCT00510575	PHASE4	COMPLETED	Surgical Outcomes Using Variable Rod Diameters in the Treatment of Idiopathic Scoliosis
NCT00768313	PHASE4	WITHDRAWN	Phase IV Comparing Rods of Yield Strengths to Correct Adolescent Idiopathic Scoliosis.
NCT00880607	PHASE4	COMPLETED	Intrathecal Morphine Versus Epidural Extended Release Morphine for Pediatric Patients Undergoing Spinal Fusion
NCT00958581	PHASE4	COMPLETED	Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery
NCT01852747	PHASE4	TERMINATED	Comparison of Actifuse ABX and Local Bone in Spinal Surgery
NCT02464813	PHASE4	COMPLETED	Effect of Pregabalin on Immediate Post-operative and Longterm Pain
NCT02465099	PHASE4	TERMINATED	Posterior Spinal Fusion With Two Energy Dissection Techniques
NCT06540885	PHASE4	RECRUITING	A Comparison Between Palonosetron Versus Granisetron as PONV Prophylaxis in Scoliotic Patients Undergoing Spine Surgery
NCT06616220	PHASE4	COMPLETED	Dexamethasone for ESPB in Pain Management After Pediatric Idiopathic Scoliosis Surgery
NCT06789016	PHASE4	COMPLETED	Dexmedetomidine for ESPB in Pain Management After Pediatric Idiopathic Scoliosis Surgery
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00323752	PHASE3	COMPLETED	Recombinant Human Erythropoietin Compared to Autologous Pre-Donation Prior to Scoliosis Surgery in Children.
NCT00684112	PHASE3	COMPLETED	Analgesic Effects of Gabapentin After Scoliosis Surgery in Children
NCT00737997	PHASE3	COMPLETED	Effect of Early Morphine Administration on the Development of Acute Opioid Tolerance During Pediatric Scoliosis Surgery
NCT01103115	PHASE3	COMPLETED	Calcium + Vitamin D Supplementation for Low Bone Mass in Adolescent Idiopathic Scoliosis (AIS)
NCT01108211	PHASE3	COMPLETED	Improving Low Bone Mass With Vibration Therapy in Adolescent Idiopathic Scoliosis (AIS)
NCT01205256	PHASE3	COMPLETED	IRB-HSR# 14145 R,S Methadone: Analgesia and Pharmacokinetics in Adolescents Undergoing Scoliosis Correction
NCT02558010	PHASE3	COMPLETED	Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion Patients
NCT03537612	PHASE3	TERMINATED	Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain
NCT00000114	PHASE3	COMPLETED	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000116	PHASE3	COMPLETED	Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00346333	PHASE3	COMPLETED	Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT04636853	PHASE3	COMPLETED	CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
NCT05537220	PHASE3	ACTIVE_NOT_RECRUITING	Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05800301	PHASE3	COMPLETED	Management of Retinitis Pigmentosa Via Combination of Wharton’s Jelly-derived Mesenchymal Stem Cells and Magnovision
NCT05926583	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
NCT06388200	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT00273598	PHASE2	COMPLETED	Comparing Two Instrumentation Systems for the Treatment of Adolescent Scoliosis
NCT01148888	PHASE2	COMPLETED	The Effect of Magnesium Sulfate on Motor and Somatosensory Evoked Potentials in Children Undergoing Scoliosis Surgery
NCT00100230	PHASE2	COMPLETED	DHA and X-Linked Retinitis Pigmentosa
NCT00447980	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447993	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT01233609	PHASE2	COMPLETED	Trial of Oral Valproic Acid for Retinitis Pigmentosa
NCT01399515	PHASE2	COMPLETED	Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
NCT01530659	PHASE2	COMPLETED	Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa